CN¥ 30.49
Key Takeaways
Risk factor
High price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Slightly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Beijing Konruns Pharmaceutical Co.,Ltd., a Chinese company established in 2003 and based in Beijing, focuses on the discovery, production, and distribution of various pharmaceutical items. Among its key offerings is Su Ling, a hemagglutinin preparation designed to minimize blood loss during surgical procedures and manage post-operative bleeding. The firm is also actively developing a pipeline of potential new medicines, such as CX1026, CX1003, and KC1036.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is reasonably priced on P/E, 'expensive' on EV
Data is available to registered users only